|
|
SFX by Ex Libris Inc. |
Contains information about title and source of a journal
Naslov: |
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). |
Vir: |
|
|
|
|
List of services to meet your request
Contains list of services for current record
Basic services |
|
|
Dodatne storitve |
|
|
© 2024 SFX by Ex Libris Inc. | Politika piškotkov
CrossRef Omogočeno
|